{
    "2019-12-31": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Pfizer Outpaces Stock Market Gains: What You Should Know",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "outpaces",
                        "stock market gains"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Here Are The Top 5 Dow Jones Laggards This Year — And Boeing Isn't The Worst",
                "features": {
                    "keywords": [
                        "Dow Jones",
                        "laggards",
                        "Boeing"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "industrials"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs",
                "features": {
                    "keywords": [
                        "drugmakers",
                        "Pfizer",
                        "GSK",
                        "price hike"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Vascepa’s Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock",
                "features": {
                    "keywords": [
                        "Vascepa",
                        "rosy",
                        "Amarin stock"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Lynparza",
                        "FDA nod",
                        "pancreatic cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Here’s Why Amarin Stock Slumped Despite the FDA Approval",
                "features": {
                    "keywords": [
                        "Amarin stock",
                        "slumped",
                        "FDA approval"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "5 Dogs of the Dow for 2020",
                "features": {
                    "keywords": [
                        "Dogs of the Dow",
                        "2020"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "diversified"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}